Omega-3 supplementation in patients with sepsis: a systematic review and meta-analysis of randomized trials. by Lu, C et al.
Lu et al. Ann. Intensive Care  (2017) 7:58 
DOI 10.1186/s13613-017-0282-5
RESEARCH
Omega-3 supplementation 
in patients with sepsis: a systematic review 
and meta-analysis of randomized trials
Clara Lu1, Sunjay Sharma2, Lauralyn McIntyre3, Andrew Rhodes4, Laura Evans5, Saleh Almenawer2, Lori Leduc6, 
Derek C. Angus7 and Waleed Alhazzani6,8,9*
Abstract 
Background: Nutritional supplementation of omega-3 fatty acids has been proposed to modulate the balance of 
pro- and anti-inflammatory mediators in sepsis. If proved to improve clinical outcomes in critically ill patients with 
sepsis, this intervention would be easy to implement. However, the cumulative evidence from several randomized 
clinical trials (RCTs) remains unclear.
Methods: We searched the Cochrane Library, MEDLINE, and EMBASE through December 2016 for RCTs on parenteral 
or enteral omega-3 supplementation in adult critically ill patients diagnosed with sepsis or septic shock. We analysed 
the included studies for mortality, intensive care unit (ICU) length of stay, and duration of mechanical ventilation, and 
used the Grading of Recommendations Assessment, Development and Evaluation approach to assess the quality of 
the evidence for each outcome.
Results: A total of 17 RCTs enrolling 1239 patients met our inclusion criteria. Omega-3 supplementation compared 
to no supplementation or placebo had no significant effect on mortality [relative risk (RR) 0.85; 95% confidence inter-
val (CI) 0.71, 1.03; P = 0.10; I2 = 0%; moderate quality], but significantly reduced ICU length of stay [mean difference 
(MD) −3.79 days; 95% CI −5.49, −2.09; P < 0.0001, I2 = 82%; very low quality] and duration of mechanical ventilation 
(MD −2.27 days; 95% CI −4.27, −0.27; P = 0.03, I2 = 60%; very low quality). However, sensitivity analyses challenged 
the robustness of these results.
Conclusion: Omega-3 nutritional supplementation may reduce ICU length of stay and duration of mechanical venti-
lation without significantly affecting mortality, but the very low quality of overall evidence is insufficient to justify the 
routine use of omega-3 fatty acids in the management of sepsis.
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Background
Sepsis is a syndrome of life-threatening organ dysfunc-
tion caused by a dysregulated host response to infection. 
Mortality from sepsis is approximately 10% when the 
Sepsis-related Organ Failure Assessment (SOFA) score 
≥2, and exceeds 40% in patients with septic shock [1]. 
Despite the advancement of best practice management 
by the Surviving Sepsis Campaign [2], the public health 
and disease burden of sepsis remains high [3–5]. As such, 
critical care research continues to search for ways to 
optimize clinical outcomes in this population, including 
through nutritional supplements [6].
Distinct changes in lipid metabolism have been noted 
in the critically ill, and the associations between nutri-
tional intervention, lipid profile, and survival are of 
considerable interest [7]. Nutritional supplementation 
with omega-3 fatty acids has been proposed to modu-
late the immune response in critical illness by inhibiting 
pro-inflammatory (eicosanoid, NF-kB) and promoting 
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anti-inflammatory (resolvin, protectin) mediators [8–11]. 
Clinical evidence for potential benefits of omega-3 fatty 
acids in acute respiratory distress syndrome (ARDS) [12, 
13] and general critical illness [14, 15] has been tempered 
by studies showing equivocal effects [16–19] and even 
potential harm [20].
Several RCTs have also investigated omega-3 sup-
plementation in sepsis over the past two decades; most 
recently, Hall et  al. [21] suggested that a reduced ratio 
of arachidonic acid (AA) to eicosapentaenoic acid and 
docosahexaenoic acid [AA/(EPA  +  DHA)] after treat-
ment with omega-3 fatty acids may be associated with 
improved survival in critically ill patients with sepsis. 
However, a comprehensive synthesis of these data has 
not been conducted, and the evidence for benefit remains 
unclear [2]. Therefore, we conducted a systematic review 
and meta-analysis of RCTs to evaluate the effect of 
omega-3 nutritional supplementation on clinical out-
comes of adult critically ill patients with sepsis or septic 
shock.
Methods
We did not publish or register a protocol for this system-
atic review.
Eligibility criteria
Eligible studies met the following criteria: (1) randomized 
clinical trial (RCT) study design; (2) the population 
involved adult patients in the intensive care unit (ICU) 
with sepsis or septic shock; (3) the intervention group 
received either enteral or parenteral supplementation 
with omega-3 fatty acids; (4) the outcomes included any 
of the following: mortality (using the longest available 
follow-up time), ICU length of stay (LOS), and duration 
of mechanical ventilation (DMV).
Search strategy
We searched MEDLINE, EMBASE, and the Cochrane 
Library from inception until December 2016. Our search 
strategies are given in Additional file 1: Tables S1–S3 and 
are limited to RCTs but not by language or publication 
date. We also screened the references from all included 
studies and relevant systematic reviews. Independently 
and in duplicate, two reviewers (CL and SS) screened 
titles and abstracts for eligibility, and conducted full-
text reviews of selected studies. Disagreements over 
study selection were resolved by discussion and consen-
sus. Studies fulfilling all of the eligibility criteria were 
included in the systematic review and meta-analysis.
Data extraction
Two reviewers (CL and SS) independently extracted data 
of interest from included studies, with disagreements 
resolved by discussion and consensus. Mortality was the 
primary outcome, and ICU LOS and DMV were second-
ary outcomes. When data were missing or unclear, we 
contacted study authors for clarification.
Risk of bias assessment
Using the Cochrane Collaboration tool [22], two review-
ers (CL and SS) independently assessed each study for 
risk of bias in seven domains: random sequence gen-
eration, allocation concealment, blinding of patients and 
personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting, and other sources 
of bias. Disagreements were resolved by discussion and 
consensus, and adjudication by a third reviewer (WA) 
when necessary. For each study, the overall risk of bias 
was judged to be high if the risk of bias was high in any 
domain, unclear if the risk of bias was unclear in any 
domain (and not high in other domains), and low if the 
risk of bias was low across all domains.
Statistical analysis
All analyses were performed using RevMan software 
(Review Manager, version 5.3. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014). 
We used inverse variance weighting and the DerSimo-
nian and Laird [23] random-effects model to pool the 
weighted effect of estimates across studies. We reported 
relative risks (RRs) with 95% confidence interval (CI) 
for dichotomous outcomes and mean differences (MDs) 
with 95% CI for continuous outcomes. In studies where 
standard deviation (SD) for ICU LOS and DMV was 
not reported, we calculated SD from other measures 
of variability (standard error (SE), interquartile range 
(IQR), or 95% CI) following the methods suggested by 
the Cochrane Collaboration [24]. We combined low- 
and high-dose omega-3 intervention groups from one 
trial [25] into a single intervention group, using formu-
lae described in the Cochrane Handbook [24] to calcu-
late combined means and SDs for relevant outcomes. We 
assessed between-studies heterogeneity using Chi-square 
and I2 statistics, with significant heterogeneity defined as 
I2 > 50% or P < 0.10 [26].
We assessed publication bias for the mortality outcome 
by visual inspection of funnel plots. We investigated het-
erogeneity between studies by performing a post hoc 
subgroup analysis comparing parenteral with enteral 
administration of omega-3. We did not perform a sub-
group analysis comparing risk of bias levels, as all studies 
had either a “high” or “unclear” overall risk of bias.
To explore the robustness of the results, we conducted 
the following post hoc sensitivity analyses: For all out-
comes, we excluded trials that used per-protocol analy-
sis, trials published in abstract form, trials that did not 
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explicitly blind patients and healthcare personnel, trials 
that administered control formulae containing omega-3, 
and trials that did not administer the control group a pla-
cebo feed. For the mortality outcome, we excluded trials 
in which eligibility for inclusion was unclear (based on 
ICU admission), and further explored odds ratio (OR) as 
an alternative to RR analysis. For the ICU LOS outcome, 
we excluded trials that did not directly report SDs. Lastly 
for the DMV outcome, we excluded trials that did not 
directly report SDs and trials that did not stratify rand-
omization by mechanical ventilation.
Quality of evidence
For each outcome of interest, we used the Grading of 
Recommendations Assessment, Development and Evalu-
ation (GRADE) approach [27] to rate the quality of evi-
dence based on risk of bias, indirectness, inconsistency, 
imprecision, and other factors. Indirectness was evalu-
ated by reviewing each trial’s study population, interven-
tion, control, and outcomes. Inconsistency was evaluated 
using between-trial Chi-square and I2 heterogeneity 
analyses. Imprecision was evaluated based on event rate, 
optimal sample size, and width of confidence intervals. 
The quality of evidence for each outcome was down-
graded one level for “serious” limitations and two levels 
for “very serious” limitations.
Results
Search results
Our search strategy identified a total of 175 citations, 
and 90 citations remained after removing duplicates. 
Screening of titles and abstracts led to the exclusion of 57 
articles and the retrieval of 33 articles for full-text assess-
ment, of which 16 were excluded for reasons outlined 
in Fig. 1. A total of 17 RCTs [25, 28–43] met our inclu-
sion criteria, representing 1239 critically ill patients with 
sepsis.
Study characteristics
Seventeen studies enrolled patients diagnosed with sep-
sis or subsets of sepsis (early sepsis [36], abdominal sep-
sis [32], severe sepsis [34, 35, 38], and septic shock [35, 
38, 41]). Three studies [31, 35, 37] required both sepsis 
and mechanical ventilation for inclusion. One study [32] 
enrolled ICU and post-anaesthesia care unit (PACU) 
patients with abdominal sepsis; we abstracted data for 
the ICU subset only.
Ten studies [29, 32–34, 38–43] used the parenteral 
route to administer omega-3 supplements, while seven 
studies [25, 28, 30, 31, 35–37] used the enteral route. 
Brand-name formulae used included Omegaven [29, 
32–34, 38, 41], Oxepa [31, 36, 37], Impact [28, 30], and 
Lipoplus [43]. Available data on the contents of all 
brand-name intervention and control formulae are given 
in Additional file 1: Tables S4–S5. Six studies calculated 
daily dose by weight [29, 31–33, 39, 40], five studies cal-
culated daily dose by basal energy expenditure (BEE) and 
the Harris Benedict equation [28, 30, 35–37], and five 
studies administered a fixed daily dose [25, 34, 38, 41, 42]; 
in one study [43], the dosing method was not specified. 
The duration of supplementation ranged between 4 and 
14 days.
While most studies administered the control group 
a placebo solution using standard enteral or parenteral 
formulae without omega-3, four studies [25, 29, 33, 41] 
assigned controls to standard sepsis care only; two of 
these explicitly defined standard care according to 2008 
Surviving Sepsis Campaign guidelines [29, 33].
For outcomes, all studies assessed mortality, twelve 
assessed ICU LOS, and seven assessed DMV. Eleven 
studies evaluated 28-day mortality [25, 31, 33–36, 39–
43], and the remainder defined mortality as 60-day [37], 
in-hospital [33], ICU [32], or left parameters undefined 
[28, 30, 38].
Six studies [28, 32, 34–36, 38] were appropriately 
blinded (patients, healthcare personnel, and research 
personnel), and seven studies [25, 29, 32, 33, 37, 39, 41] 
conducted a full intention-to-treat analysis of data. Six 
studies [28–31, 35, 36] were industry-funded. Finally, one 
study [32] was published solely as an abstract, but the 
authors provided missing data via personal communica-
tion. Table 1 presents further details of eligible studies.
Risk of bias
Using the Cochrane Collaboration tool for risk of bias 
[22], twelve studies were judged to be at high risk of bias, 
many of these due to attrition and performance bias. Risk 
of bias was unclear for the remaining five studies (Fig. 2).
Quality of evidence
Table 2 presents our GRADE [27] assessment of the qual-
ity of evidence by outcome. Evidence quality was assessed 
as moderate for mortality and very low for both ICU LOS 
and DMV outcomes.
Main outcomes
Mortality was reported by 17 trials enrolling 1239 
patients (Fig.  3). Omega-3 was not associated with a 
significant reduction in mortality (RR 0.85; 95% CI 
0.71, 1.03; P  =  0.10; I2  =  0%; moderate quality). ICU 
length of stay was reported in 12 trials enrolling 925 
patients (Fig.  4). There was a significant reduction 
in ICU LOS (MD −3.79  days; 95% CI −5.49, −2.09; 
P < 0.0001, I2 = 82%; very low quality) for patients sup-
plemented with omega-3. Duration of mechanical venti-
lation was reported in seven trials enrolling 495 patients 
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Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart: description of the study selection process. Seven-
teen trials (1 abstract and 16 fully published trials) were eligible and included in the qualitative and quantitative analyses. ICU, intensive care unit
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(Fig. 5). There was a significant reduction in DMV (MD 
−2.27  days; 95% CI −4.27, −0.27; P  =  0.03, I2  =  60%; 
very low quality) in the group of patients supplemented 
with omega-3.
Subgroup and sensitivity analyses
Ten studies used parenteral administration and seven 
studies used enteral administration of omega-3. We per-
formed a post hoc subgroup analysis comparing these 
subgroups for the outcome of mortality (Additional 
file 1: Figure S1) and found no significant differences in 
treatment effect (P =  0.97, I2 =  0%) between trials that 
used parenteral (RR 0.89; 95% CI 0.66, 1.19; P  =  0.42; 
I2 = 0%) compared to enteral (RR 0.88; 95% CI 0.64, 1.21; 
P = 0.43; I2 = 35%) routes. However, the analysis is con-
founded by another major difference between subgroups: 
Most enteral formulations administered omega-3 in 
combination with other supplements (including arginine, 
selenium, and mRNA), while all parenteral formulations 
administered omega-3 as the sole supplement. Since the 
distinct influences of these two characteristics (additional 
supplementation and route of administration) on the 
treatment effect cannot be distinguished, no definitive 
conclusions can be drawn from this analysis.
Sensitivity analyses excluding trials that used per-pro-
tocol analysis [28, 30, 31, 34–36, 38, 40, 42, 43] and trials 
that used control formulae containing omega-3 [31, 36] 
produced congruent results for all three outcomes. For 
the mortality outcome, exclusion of trials in which ICU 
admission was unclear [39], trials published in abstract 
form [32], trials without explicit blinding of patients and 
healthcare personnel [25, 29–31, 33, 37, 39–43], and trials 
that did not administer the control group a placebo feed 
[25, 29, 33, 41] yielded similar non-significant results.
However, for the ICU LOS outcome, exclusion of tri-
als that did not explicitly blind patients and healthcare 
personnel to the intervention [25, 30, 31, 33, 37, 40–43] 
rendered the significant reduction in ICU LOS non-
significant (MD −3.63; 95% CI −7.85, 0.60; P  =  0.09, 
I2  =  85%). Similarly, the significant reduction in DMV 
was countered by the exclusion of trials that did not 
explicitly blind patients and healthcare personnel [25, 30, 
31, 37, 43] (MD −4.63; 95% CI −10.00, 0.75; P =  0.09, 
I2 =  70%), trials that did not stratify mechanically ven-
tilated patients during randomization [25, 30, 36] (MD 
−1.78 days; 95% CI −4.39, 0.83; P = 0.18, I2 = 61%), tri-
als that did not administer the control group a placebo 
feed [25] (MD −2.10 days; 95% CI −4.48, 0.29; P = 0.08, 
I2 = 65%), and trials published in abstract form [32] (MD 
−2.32  days; 95% CI −4.86, 0.22; P  =  0.07, I2  =  67%). 
Details of these analyses are given in Additional file  1: 
Tables S6–S8.
Fig. 2 Risk of bias assessment of the included trials using the 
Cochrane Collaboration tool. Individual risk of bias assessments across 
seven domains: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of outcome 
assessment, incomplete outcome data, selective reporting, and other 
bias. Risk of bias levels: low (green), unclear (yellow), high (red)
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Fig. 3 Mortality outcome. Data from 17 trials (n = 1239 patients) were included and analysed using the random-effects model. Omega-3 supple-
mentation was associated with a non-significant reduction in mortality. ICU intensive care unit, IV inverse variance, RCT randomized clinical trial
Fig. 4 ICU length of stay outcome. Data from 12 trials (n = 925 patients) were included and analysed using the random-effects model. Omega-3 
supplementation was associated with a significantly lower length of stay in ICU. IV inverse variance
Fig. 5 Duration of mechanical ventilation outcome. Data from 7 trials (n = 495 patients) were included and analysed using the random-effects 
model. Omega-3 supplementation was associated with a significantly shorter duration of mechanical ventilation. IV inverse variance
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Publication bias
Visual inspection of funnel plots for the mortality and 
ICU LOS outcomes (Additional file 1: Figures S2–S3) did 
not reveal small-study effects suggestive of publication 
bias.
Discussion
Our meta-analysis of 17 RCTs (1239 patients) suggests, 
based on moderate-quality evidence, that omega-3 sup-
plementation does not significantly reduce mortality in 
septic critically ill patients, with the absolute effect rang-
ing from 77 fewer to 8 more deaths per 1000 patients. 
Very low-quality evidence also suggests that omega-3 
may reduce length of ICU stay and duration of mechani-
cal ventilation, but these results are challenged by multi-
ple sensitivity analyses.
A recent meta-analysis of eleven RCTs (808 patients) 
[44] also explored omega-3 in the critically ill with sep-
sis and similarly found a non-significant reduction in 
mortality (RR 0.84; 95% CI 0.67 to 1.05; P = 0.12) and a 
significant reduction in DMV (MD −3.82 days; 95% CI 
−4.61 to −3.04; P < 0.001). However, the authors did not 
find a significant reduction in ICU LOS (MD −2.70 days; 
95% CI −6.40 to 1.00; P = 0.15). Key differences in their 
analysis include the search of a single database (Pub-
Med), the use of the Jadad score to assess risk of bias 
[45], the absence of six studies included in our analysis 
[25, 28, 39–42], and the inclusion of one study excluded 
from our analysis for enrolling patients without sepsis 
[46].
Another meta-analysis of twelve RCTs (721 patients) 
evaluated the effects of parenteral omega-3 in sepsis 
[47]. Their analysis revealed a significant reduction in 
28-day mortality (RR 0.77, 95% CI 0.59 to 0.99, P = 0.04) 
and ICU LOS (MD −3.10 days; 95% CI −5.98 to −0.21; 
P  =  0.04) and a non-significant effect on DMV (MD 
1.33  days; 95% CI −5.09 to 7.75; P  =  0.69). Here the 
inconsistencies with our meta-analysis may be explained 
by the exclusion of trials using enteral omega-3, the 
inclusion of one study excluded from our analysis for 
enrolling patients without sepsis [46], and the absence of 
more recently published RCTs [29, 33, 38].
Beyond the potential reductions in DMV and ICU 
LOS suggested by the present meta-analysis, the risks 
and costs of omega-3 supplementation must also be 
addressed. Although the cost of omega-3 supplementa-
tion varies by dose, frequency, route of administration, 
and choice of formula, the leading parenteral formula 
used in this meta-analysis (Omegaven) has been reported 
to cost up to 3 times more than another lipid emulsion 
in conventional use [48]. According to its manufacturer, 
Omegaven in North America is currently obtained only 
by applying to special access programs.
Safety is another key consideration. While most RCTs 
studying omega-3 supplementation in critical illness have 
reported minimal adverse effects, others have identified 
important risks that include significantly longer hospi-
tal and ICU lengths of stay [30, 34], increased duration 
of mechanical ventilation [47], fewer ventilator-free and 
ICU-free days [20], elevated triglyceride levels [29, 37], 
and a higher incidence of diarrhoea [20, 25]. Most con-
cerning are reported trends towards increased mortality 
[20, 28, 31, 39, 49]. Even in meta-analyses that demon-
strate a non-significant reduction in mortality [18, 44, 
50, 51], as this one does, the upper limit of the CI can-
not exclude the potential for increased mortality with 
omega-3 supplementation. Detailed data on non-surviv-
ing patients would be necessary to explore characteristics 
associated with increased mortality risk with omega-3 
supplementation.
Limitations that call for cautious interpretation of these 
findings exist at both the study and review level. Dosing 
and route of administration varied across trials; whether 
these characteristics modify the treatment effect has not 
been sufficiently studied for omega-3, and our subgroup 
analysis comparing enteral and parenteral routes was 
inconclusive. Recognizing that several trials administered 
omega-3 in combination with other supplements, we 
downgraded the quality of evidence across outcomes for 
indirectness of intervention. For ICU LOS and DMV, we 
further downgraded the quality of evidence for signifi-
cant heterogeneity and high overall risk of bias.
Strengths of this meta-analysis include its comprehen-
sive database search, literature assessments conducted 
independently and in duplicate, the expertise of a reg-
istered dietician, the use of the Cochrane Collaboration 
Tool [22] to assess risk of bias, and careful adherence 
to the GRADE approach [27] and PRISMA guidelines 
[52]. It addresses a specific question and includes recent 
eligible trials. To date, this is the largest meta-analysis 
conducted on the effect of omega-3 supplementation in 
critically ill patients with sepsis.
Conclusions
Our meta-analysis should prompt caution against the 
routine use of omega-3 fatty acid supplementation for 
critically ill patients with sepsis. While very low-quality 
evidence suggests that omega-3 may reduce the number 
of days patients spend on mechanical ventilation and in 
the ICU, these effects are overturned by multiple sensi-
tivity analyses. Moderate-quality evidence also demon-
strates a non-significant trend towards reduced mortality, 
yet the upper limit of confidence reveals potential for 
harm. Here, even the slightest possibility of increased 
mortality (moderate-quality evidence) demonstrated in 
the present and previous meta-analyses still outweighs 
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the potential benefits of reduced ICU LOS and DMV 
(very low-quality evidence).
With current evidence limited in quality and quan-
tity, the profile of risk and benefit does not favour treat-
ment of sepsis with omega-3. Justification for omega-3 
in sepsis will require large-scale, high-quality RCTs that 
strengthen the evidence for clinical benefit enough to 
outweigh the risks and costs of this intervention [53]. 
Until then, the routine use of omega-3 fatty acid supple-
mentation in patients with sepsis should be avoided.
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